McClung MR et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821–831
Denosumab is a fully human monoclonal antibody that targets RANKL (the receptor activator of nuclear factor κB ligand)—a protein that acts as the primary mediator of osteoclast differentiation, activity, and lifespan. In a phase II, randomized, placebo-controlled study, McClung et al. evaluated the efficacy of denosumab in postmenopausal women younger than 80 years who had a low BMD.
In total, 369 women from 29 study centers in the US completed this 12-month study. Participants were randomly assigned to receive subcutaneous denosumab, either every 3 months (6, 14, or 30 mg) or every 6 months (4, 60, 100, or 210 mg), open-label 70 mg alendronate per week, or placebo. At 12 months, women who received denosumab had a mean increase in BMD of 3.0–6.7% at the lumbar spine, compared with a 4.6% increase and a 0.8% decrease in women who received alendronate and placebo, respectively. Women who received denosumab also had a greater increase in total hip BMD and BMD in the distal third of the radius compared with the alendronate and placebo groups. Levels of serum C-TELOPEPTIDE decreased as early as 3 days in women who received denosumab. A dose of 30 mg denosumab every 3 months, or 60 mg every 6 months seemed to be the most effective regimens. Adverse events were not significantly different among the three treatment arms.
The authors conclude that denosumab administered subcutaneously to postmenopausal women causes a decrease in bone turnover and an increase in BMD. Denosumab might, therefore, be an effective treatment for osteoporosis.
Rights and permissions
About this article
Cite this article
Lofthouse, M. Denosumab improves low BMD in postmenopausal women. Nat Rev Endocrinol 2, 249 (2006). https://doi.org/10.1038/ncpendmet0156
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0156